Epidemic pertussis and acellular pertussis vaccine failure in the 21st century

Pediatrics

Volumn 135, Issue 6, 2015, Pages 1130-1132

  Cherry, James D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; EPITOPE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE;

ANTIBODY DECAY; ANTIBODY PATTERN; BORDETELLA PERTUSSIS; CROSS REACTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FIMBRIA; HUMAN; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; NOTE; PERTUSSIS; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL; UNITED STATES; VACCINE FAILURE; FEMALE; MALE; WHOOPING COUGH;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; WHOOPING COUGH;

EID: 84930606462     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-4118     Document Type: Note

References (26)

1. Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135(6):981-989
2. Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanusdiphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942-953
3. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis. 1987;9(5):866-883
4. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012;129(5):968-970
5. Cherry JD. Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785-787
6. Cherry JD. Pertussis: challenges today and for the future. PLoS Pathog. 2013;9(7):1-3
7. Cherry JD. The present and future control of pertussis. Clin Infect Dis. 2010;51(6):663-667
8. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis. 2001;183(9):1353-1359
9. Ward JI, Cherry JD, Chang SJ, et al APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555-1563
10. Cherry JD, Heininger U, Stehr K, Christenson P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics. 1998;102(4 pt 1):909-912
11. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111(2):787-792
12. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 2013;6(4):787-796
13. Cherry JD, Heininger U, Richards DM, et al. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol. 2010;17(5):741-747
14. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907-1916
15. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901-1906
16. Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119-125
17. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454-456
18. Cherry JD, Olin P. The science and fiction of pertussis vaccines. Pediatrics. 1999;104(6):1381-1383
19. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of an acellular pertussiscomponent diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J Pediatr. 1990;117(1 pt 1):46-51
20. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR; Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009;123(1):301-312
21. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis. 2004;38(4):591-594
22. Hodder SL, Cherry JD, Mortimer EA Jr, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000;31(1):7-14
23. Le T, Cherry JD, Chang SJ, et al APERT Study. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis. 2004;190(3):535-544
24. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18(2):326-382
25. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis. 2015;60(3):333-337
26. Cherry JD. Tetanus-diphtheria-pertussis immunization in pregnant women and the prevention of pertussis in young infants. Clin Infect Dis. 2015;60(3):338-340